Compare MNKD & ASST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MNKD | ASST |
|---|---|---|
| Founded | 1991 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2004 | 2022 |
| Metric | MNKD | ASST |
|---|---|---|
| Price | $3.85 | $11.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | $8.69 | ★ $23.50 |
| AVG Volume (30 Days) | ★ 4.7M | 2.9M |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.56 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $348,966,000.00 | $633,489.00 |
| Revenue This Year | $35.81 | $294.91 |
| Revenue Next Year | $11.89 | $12.16 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 22.23 | ★ 128.67 |
| 52 Week Low | $2.23 | $0.49 |
| 52 Week High | $6.51 | $19.75 |
| Indicator | MNKD | ASST |
|---|---|---|
| Relative Strength Index (RSI) | 47.65 | 41.82 |
| Support Level | $3.81 | $10.79 |
| Resistance Level | $3.94 | $12.25 |
| Average True Range (ATR) | 0.21 | 0.78 |
| MACD | -0.04 | 0.05 |
| Stochastic Oscillator | 34.25 | 20.51 |
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
Strive Inc is a structured finance company and institutional asset manager focused on disciplined capital allocation and long term value creation. The company has adopted bitcoin as its hurdle rate for capital deployment because of its fiduciary duty to maximize long-term value for stockholders, and compounding purchasing power over time. It operates in two reportable operating segments: the Asset Management segment, which provides investment advisory services and the Corporate & Other segment, which includes the company's bitcoin treasury operations. The majority of the revenue is derived from the Asset Management segment.